3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Unknown
12
Completed
8
Recruiting
5
Terminated
2
Active not recruiting
2
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Conditions
Head and Neck Neoplasms
276
Squamous Cell Carcinoma of Head and Neck
241
Carcinoma, Non-Small-Cell Lung
86
Melanoma
68
Neoplasms
61
Colorectal Neoplasms
52
Neoplasm Metastasis
48
Carcinoma, Squamous Cell
48
Thyroid Neoplasms
47
Breast Neoplasms
41
Carcinoma, Renal Cell
36
Lung Neoplasms
34
Ovarian Neoplasms
33
Oropharyngeal Neoplasms
30
Stomach Neoplasms
29
Mouth Neoplasms
29
Nasopharyngeal Carcinoma
28
Triple Negative Breast Neoplasms
26
Uterine Cervical Neoplasms
25
Sarcoma
25
Laryngeal Neoplasms
24
Pancreatic Neoplasms
23
Esophageal Neoplasms
23
Salivary Gland Neoplasms
21
Urinary Bladder Neoplasms
20
Recurrence
19
Nasopharyngeal Neoplasms
18
Small Cell Lung Carcinoma
17
Carcinoma, Transitional Cell
17
Prostatic Neoplasms
16
Interventions
donafenib
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Differentiated Thyroid Cancer
×
Head & Neck
×
Clear all
NCT03602495
2021-12-13
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
Terminated
204 enrolled
NCT01843062
2019-08-28
ASTRA
AstraZeneca
Phase 3
Terminated
233 enrolled
14 charts